COVID-19 疫苗接种后异常子宫出血的诊断与诊疗
在大型整合医疗系统中,基于 2019 年 1 月至 2021 年 12 月的分段回归分析显示,COVID-19 疫苗可用性与 16 至 44 岁未绝经女性每月人群异常子宫出血新诊断率无显著关联;比较 2717 例新诊断患者,近期接种者出血严重程度相似或更轻;114 例接种后出血病例中约三分之一未接受诊断性检查,57% 电子病历未记录出血病因。
要点
- COVID-19 疫苗可用性与异常子宫出血新诊断率的水平或趋势变化无显著关联。
- 近期接种疫苗者的异常出血严重程度与未接种者或接种超过 60 天者相似或更轻。
- 接种后出血病例最常见症状为出血时间、持续时间和量的变化,约三分之一未接受诊断性检查。
核心结论
- COVID-19 疫苗可用性与研究人群中超过 79,000 名育龄女性异常子宫出血的医疗就诊发生率变化无关。
- 在疫苗可用后期间诊断的 2717 例异常子宫出血患者中,接种疫苗与出血严重程度增加无关。
研究设计与样本
- 采用分段回归评估 COVID-19 疫苗可用性与每月人群异常子宫出血新诊断率变化的关系,对象为 16 至 44 岁未绝经的医疗系统成员。
- 比较 2020 年 12 月至 2021 年 10 月 13 日期间新诊断异常子宫出血患者的临床和人口学特征,按接种状态分为从未接种、诊断前 60 天内接种、诊断前超过 60 天接种。
- 对同一时间段内接种 COVID-19 疫苗后 1 至 60 天内诊断异常子宫出血的患者进行详细病历审查。
主要发现
- 每月女性成员数在 79,000 至 85,000 之间,异常子宫出血诊断发生率范围为每 10 万人日 8.97 至 19.19。
- 大流行前(2019 年 1 月至 2020 年 1 月)与 COVID-19 疫苗后(2020 年 12 月至 2021 年 12 月)期间,异常子宫出血诊断发生率的水平或趋势无显著变化。
- 按接种状态比较 2717 例异常子宫出血病例的临床特征,近期接种者的异常出血与从未接种者或接种超过 60 天者相似或更轻。
- 按接种状态,新诊断异常子宫出血患者的年龄和种族存在显著差异(P<.02);从未接种者最年轻,接种超过 60 天者最年长;从未接种者中黑种人/非裔美国人比例最高,接种者中亚裔比例更高。
- 对 2020 年 12 月至 2021 年 10 月 13 日期间诊断的 114 例确诊接种后异常子宫出血病例进行病历审查,最常见症状为出血时间、持续时间和量的变化;约三分之一病例未接受诊断性检查;57% 的电子病历未记录出血病因;12% 的病例提及或询问出血与近期 COVID-19 疫苗的可能关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is evidence suggesting that COVID-19 vaccination may be associated with small, transitory effects on uterine bleeding, possibly including menstrual timing, flow, and duration, in some individuals. However, changes in health care seeking, diagnosis, and workup for abnormal uterine bleeding in the COVID-19 vaccine era are less clear. OBJECTIVE: This study aimed to assess the impact of COVID-19 vaccination on incident abnormal uterine bleeding diagnosis and diagnostic evaluation in a large integrated health system. STUDY DESIGN: Using segmented regression, we assessed whether the availability of COVID-19 vaccines was associated with changes in monthly, population-based rates of incident abnormal uterine bleeding diagnoses relative to the prepandemic period in health system members aged 16 to 44 years who were not menopausal. We also compared clinical and demographic characteristics of patients diagnosed with incident abnormal uterine bleeding between December 2020 and October 13, 2021 by vaccination status (never vaccinated, vaccinated in the 60 days before diagnosis, vaccinated >60 days before diagnosis). Furthermore, we conducted detailed chart review of patients diagnosed with abnormal uterine bleeding within 1 to 60 days of COVID-19 vaccination in the same time period. RESULTS: In monthly populations ranging from 79,000 to 85,000 female health system members, incidence of abnormal uterine bleeding diagnosis per 100,000 person-days ranged from 8.97 to 19.19. There was no significant change in the level or trend in the incidence of abnormal uterine bleeding diagnoses between the prepandemic (January 2019-January 2020) and post-COVID-19 vaccine (December 2020-December 2021) periods. A comparison of clinical characteristics of 2717 abnormal uterine bleeding cases by vaccination status suggested that abnormal bleeding among recently vaccinated patients was similar or less severe than abnormal bleeding among patients who had never been vaccinated or those vaccinated >60 days before. There were also significant differences in age and race of patients with incident abnormal uterine bleeding diagnoses by vaccination status (Ps<.02). Never-vaccinated patients were the youngest and those vaccinated >60 days before were the oldest. The proportion of patients who were Black/African American was highest among never-vaccinated patients, and the proportion of Asian patients was higher among vaccinated patients. Chart review of 114 confirmed postvaccination abnormal uterine bleeding cases diagnosed from December 2020 through October 13, 2021 found that the most common symptoms reported were changes in timing, duration, and volume of bleeding. Approximately one-third of cases received no diagnostic workup; 57% had no etiology for the bleeding documented in the electronic health record. In 12% of cases, the patient mentioned or asked about a possible link between their bleeding and their recent COVID-19 vaccine. CONCLUSION: The availability of COVID-19 vaccination was not associated with a change in incidence of medically attended abnormal uterine bleeding in our population of over 79,000 female patients of reproductive age. In addition, among 2717 patients with abnormal uterine bleeding diagnoses in the period following COVID-19 vaccine availability, receipt of the vaccine was not associated with greater bleeding severity.
引用
- Brooks N, Irving SA, Kauffman TL, et al. Abnormal uterine bleeding diagnoses and care following COVID-19 vaccination. Am J Obstet Gynecol. 2024. PMID: 38219855. doi:10.1016/j.ajog.2024.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。